Application of an epitope-based allocation system in pediatric kidney transplantation

被引:47
作者
Kausman, Joshua Y. [1 ,2 ,3 ]
Walker, Amanda M. [1 ,2 ,3 ]
Cantwell, Linda S. [4 ]
Quinlan, Catherine [1 ,2 ,3 ]
Sypek, Matthew P. [1 ,3 ]
Ierino, Francesco L. [1 ,3 ,5 ]
机构
[1] Royal Childrens Hosp Melbourne, Dept Nephrol, Parkville, Vic 3052, Australia
[2] Murdoch Childrens Res Inst, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
[4] Australian Red Cross Blood Serv, Victorian Immunogenet & Transplantat Serv, Melbourne, Vic, Australia
[5] Austin Hlth, Dept Nephrol, Melbourne, Vic, Australia
关键词
donor-specific antibody; epitope; kidney; pediatric; transplant; HUMAN-LEUKOCYTE-ANTIGEN; MOLECULARLY BASED ALGORITHM; HIGHLY SENSITIZED PATIENTS; DONOR-SPECIFIC ANTIBODIES; GRAFT LOSS; HISTOCOMPATIBILITY DETERMINATION; RENAL-TRANSPLANTATION; CHRONIC REJECTION; PATIENT OUTCOMES; RECIPIENTS;
D O I
10.1111/petr.12815
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Donor-recipient HLA mismatch remains a leading cause for sensitization and graft loss in kidney transplantation. HLA compatibility at an epitope level is emerging as an improved method of matching compared with current HLA antigen allocation. A novel epitope-based allocation approach to prospectively exclude donors with high-level mismatches was implemented for pediatric KTRs on the DD waiting list. Nineteen consecutive transplants were followed for 12 months, including eight DD KTRs listed with eplet exclusions, as well as three DD KTRs and eight LD KTRs without exclusions. KTRs with eplet exclusions had estimated GFR of 78.5 mL/min/1.73 m(2), no episodes of rejection, and time to transplant 6.55 months. HLA-A, HLA-B, HLA-DR antigen mismatches were similar between all groups. KTRs with exclusions had significantly lower class II eplet mismatches (20.4) than the contemporary DD KTRs without exclusions (63.7) and DD KTRs transplanted in the preceding decade (46.9). dnDSAs were identified in two of eight DD KTRs with exclusions, two of three DD KTRs without exclusions and five of eight LD KTRs. Epitope-based allocation achieved timely access to transplantation, low class II eplet mismatches, and low rates of dnDSAs in the first year. This strategy requires longer follow-up and larger numbers, but has the potential to reduce anti-HLA sensitization and improve both graft survival and opportunities for future retransplantation.
引用
收藏
页码:931 / 938
页数:8
相关论文
共 41 条
  • [1] Changes in Pediatric Renal Transplantation After Implementation of the Revised Deceased Donor Kidney Allocation Policy
    Agarwal, S.
    Oak, N.
    Siddique, J.
    Harland, R. C.
    Abbo, E. D.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (05) : 1237 - 1242
  • [2] Brouhard B H, 2000, Pediatr Transplant, V4, P261, DOI 10.1034/j.1399-3046.2000.00121.x
  • [3] The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome
    Claas, FHJ
    Witvliet, MD
    Duquesnoy, RJ
    Persijn, GG
    Doxiadis, IIN
    [J]. TRANSPLANTATION, 2004, 78 (02) : 190 - 193
  • [4] The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens
    Dankers, MKA
    Witvliet, MD
    Roelen, DL
    De Lange, P
    Korfage, N
    Persijn, GG
    Duquesnoy, R
    Doxiadis, IIN
    Claas, FHJ
    [J]. TRANSPLANTATION, 2004, 77 (08) : 1236 - 1239
  • [5] Should HLA Mismatch Acceptability for Sensitized Transplant Candidates Be Determined at the High-Resolution Rather Than the Antigen Level?
    Duquesnoy, R. J.
    Kamoun, M.
    Baxter-Lowe, L. A.
    Woodle, E. S.
    Bray, R. A.
    Claas, F. H. J.
    Eckels, D. D.
    Friedewald, J. J.
    Fuggle, S. V.
    Gebel, H. M.
    Gerlach, J. A.
    Fung, J. J.
    Middleton, D.
    Nickerson, P.
    Shapiro, R.
    Tambur, A. R.
    Taylor, C. J.
    Tinckam, K.
    Zeevi, A.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 (04) : 923 - 930
  • [6] Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications
    Duquesnoy, R. J.
    [J]. TISSUE ANTIGENS, 2011, 77 (06): : 525 - 534
  • [7] HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A,B amino acid triplet level on kidney transplant survival
    Duquesnoy, RJ
    Takemto, S
    de Lange, P
    Doxiadis, IIN
    Schreuder, GMT
    Persijn, GG
    Claas, FHJ
    [J]. TRANSPLANTATION, 2003, 75 (06) : 884 - 889
  • [8] HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. IV. An alternative strategy to increase the number of compatible donors for highly sensitized patients
    Duquesnoy, RJ
    Howe, J
    Takemoto, S
    [J]. TRANSPLANTATION, 2003, 75 (06) : 889 - 897
  • [9] Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts
    Everly, Matthew J.
    Rebellato, Lorita M.
    Haisch, Carl E.
    Ozawa, Miyuki
    Parker, Karen
    Briley, Kimberly P.
    Catrou, Paul G.
    Bolin, Paul
    Kendrick, William T.
    Kendrick, Scott A.
    Harland, Robert C.
    Terasaki, Paul I.
    [J]. TRANSPLANTATION, 2013, 95 (03) : 410 - 417
  • [10] EPITOPE MAP OF THE HLA-B7 CREG USING AFFINITY-PURIFIED HUMAN ALLOANTIBODY PROBES
    FULLER, AA
    RODEY, GE
    PARHAM, P
    FULLER, TC
    [J]. HUMAN IMMUNOLOGY, 1990, 28 (03) : 306 - 325